Population based screening for chronic kidney disease: cost effectiveness study. - Wikidata - awgldk - TriplyDB

Population based screening for chronic kidney disease: cost effectiveness study.

Population based screening for chronic kidney disease: cost effectiveness study.

http://www.wikidata.org/entity/Q34286311

about

Methods Used in Economic Evaluations of Chronic Kidney Disease Testing - A Systematic Review Mass screening for chronic kidney disease in rural and remote Canadian first nations people: methodology and demographic characteristics.Opportunity cost of funding drugs for rare diseases: the cost-effectiveness of eculizumab in paroxysmal nocturnal hemoglobinuria Reducing the costs of chronic kidney disease while delivering quality health care: a call to action.A review of linked health data in Australian nephrology.Implementation of a pragmatic randomized trial of screening for chronic kidney disease to improve care among non-diabetic hypertensive veterans The Financial Impact of Advanced Kidney Disease on Canada Pension Plan and Private Disability Insurance Costs.Early diagnosis saves lives: focus on patients with chronic kidney disease A Case for Early Screening for Diabetic Kidney Disease.Risk Prediction for Early CKD in Type 2 Diabetes.Adding specialized clinics for remote-dwellers with chronic kidney disease: a cost-utility analysis.Cost effectiveness of strategies to combat cardiovascular disease, diabetes, and tobacco use in sub-Saharan Africa and South East Asia: mathematical modelling study.Development and demonstration of a state model for the estimation of incidence of partly undetected chronic diseases Cost-effectiveness of chronic kidney disease mass screening test in Japan.Risk factors associated with disease progression and mortality in chronic kidney disease of uncertain etiology: a cohort study in Medawachchiya, Sri Lanka.Tubulointerstitial damage as the major pathological lesion in endemic chronic kidney disease among farmers in North Central Province of Sri Lanka The cost-effectiveness of using chronic kidney disease risk scores to screen for early-stage chronic kidney disease.Prevalence estimates of chronic kidney disease in Canada: results of a nationally representative survey Approach to economic evaluation in primary care: review of a useful tool for primary care reform.The See Kidney Disease Targeted Screening Program for CKD.Lifetime incidence of CKD stages 3-5 in the United States.Update on cystatin C: incorporation into clinical practice.Value-based integrated (renal) care: setting a development agenda for research and implementation strategies.The Oxford Renal (OxRen) cross-sectional study of chronic kidney disease in the UK.Economic evaluation of frequent home nocturnal hemodialysis based on a randomized controlled trial.To RAS or not to RAS? The evidence for and cautions with renin-angiotensin system inhibition in patients with diabetic kidney disease.Diabetic kidney disease in Australia: current burden and future projections.Estimating One-Year Risk of Incident Chronic Kidney Disease: Retrospective Development and Validation Study Using Electronic Medical Record Data From the State of Maine.A systematic review of economic evaluations of screening programmes for cardiometabolic diseases.Association between undiagnosed hypertension and microalbuminuria in South Asians without known diabetes.eMAP:CKD: electronic diagnosis and management assistance to primary care in chronic kidney disease.Age and gender differences in the relationship between hepatitis C infection and all stages of Chronic kidney disease.Screening Strategies for Unrecognized CKD.Chronic kidney disease in low-income to middle-income countries: the case for increased screening To screen or not to screen: that is not (yet) the question.Innovative non-invasive model for screening reduced estimated glomerular filtration rate in a working population.Cost-effectiveness of screening type 2 diabetes patients for chronic kidney disease progression with the CKD273 urinary peptide classifier as compared to urinary albumin excretion.High prevalence of risk factors for chronic kidney disease in Balkan endemic nephropathy foci.Screening of a population at risk of chronic kidney disease: analysis of factors associated with low eGFR and microalbuminuria.

P2860

Q26783181-C668675E-BDA3-4954-98A7-3C440FA2A3C1 Q27316071-F7B8337B-03D1-410A-AE68-6D366CFB82C3 Q28243221-4BD212B9-2666-461E-BB35-F9D380744BA1 Q30234324-838F0BAF-92EC-421A-A21D-7D102542296B Q30383349-2D4E72B6-A362-43C8-8823-AD2DA990F977 Q33556410-DF9F905D-823D-480B-AE85-398DC0BAC5F9 Q33606664-AAC4400A-A2A8-4C32-85F4-EC3F89E38DE7 Q33873045-7D68A707-2648-4678-A0B3-3D2595D4C7D2 Q35567422-0728902A-AAC5-4E5C-9700-F43A49458606 Q35691583-DBBC15E9-64BE-45A3-B738-D55C136E7C53 Q35692458-B370C67F-9401-4223-8BA1-A7BC554FB08D Q35798096-554D22EF-0CD6-4F78-AF62-358F03E5AB32 Q35839149-D67B7735-129B-48F8-970C-4AB078CBA0C0 Q35895018-10B3E6FF-0218-47FA-A19A-D5CE85840B78 Q35946436-F7F58554-FD26-41F3-AB7D-64B513667012 Q35946465-3089607D-D1B6-408A-B0CB-3506AEFAA926 Q36306581-BD2A9BE0-49B7-499E-976A-FDDB27DEEDFE Q36923413-1DDE24CC-460D-4E86-B233-4D74F2E4EDC7 Q36925988-23C40888-EA16-443A-BDC4-4FB26ACA7E6F Q36965146-21BBF897-4C25-4305-9514-510FC623D4F8 Q37045873-0B7A0A8E-5B6A-4B37-B845-B379B7D14248 Q37126287-C241612F-0EB9-437B-83F4-02E1E74FB61C Q37145847-BFDA4FFD-7E1C-4D8A-A590-33C9BC98EE59 Q37448579-D55601D8-9A14-4606-9D28-1DEC62D5C033 Q37604731-C56B2728-B7C0-4666-ADE3-CF207E8418CB Q38098108-34B2997C-4A9F-4B75-83F6-B7047A76ADCF Q38216851-A2FB8828-3E24-47FC-9197-D330EEF92076 Q38659530-FB568A7D-B22E-49A3-9F4C-B59440AE41A8 Q38775859-F264089F-B67E-4660-BD95-8C89412DBB54 Q39145398-266E40D8-4DDC-4777-B876-9DB4C48D57FE Q39241452-A99466E0-5068-43ED-9317-C875A8E01E4B Q42251188-B59B2ADA-1800-4B08-9012-FF1C94C50A91 Q42743349-ABEDDAE5-20F4-433C-B27F-9E90FF109672 Q42764188-B24F47A0-30F0-4EB7-B9DD-2926707B90A5 Q43218213-C4963B82-7F2A-4B0B-8AA1-5F10EBD78DFF Q48355578-152D0573-22BB-477C-9323-4FE52E7151CD Q48610499-8A157637-1D97-457D-9FB2-F1A544876346 Q51357546-88F9C63B-914F-42BA-B8EC-A0630BC29040 Q51412159-EB033089-58EC-4BD9-8C03-D014699675E0

P2860

Population based screening for chronic kidney disease: cost effectiveness study.

http://www.wikidata.org/entity/Q34286311

description

2010 nî lūn-bûn

@nan

2010 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Population based screening for chronic kidney disease: cost effectiveness study.

@ast

Population based screening for chronic kidney disease: cost effectiveness study.

@en

Population based screening for chronic kidney disease: cost effectiveness study.

@nl

type

label

Population based screening for chronic kidney disease: cost effectiveness study.

@ast

Population based screening for chronic kidney disease: cost effectiveness study.

@en

Population based screening for chronic kidney disease: cost effectiveness study.

@nl

prefLabel

Population based screening for chronic kidney disease: cost effectiveness study.

@ast

Population based screening for chronic kidney disease: cost effectiveness study.

@en

Population based screening for chronic kidney disease: cost effectiveness study.

@nl

P1433

Q34286311-F82F2D2D-D124-42CA-BB90-65C5BB9B4926

P1476

Q34286311-A258D0F0-3DE8-4EAD-8C59-9478AC2F2E95

P2093

Q34286311-172B73AD-22B6-4990-905F-C34279DF794F

Q34286311-52AAE8C8-8469-4925-A5B3-D7EF837B7728

Q34286311-728903D2-1FCB-427E-BE2E-0769AA3FEB8F

Q34286311-B5B6E386-AEE4-4839-8069-44E2B4F079F3

Q34286311-BF5F0E3A-EB08-4DC3-BD57-BF9758496DC2

Q34286311-FFE407D7-4A49-426D-91E3-E5695ED9A4E3

P2860

Q34286311-008A107A-BC3E-45FB-80D4-45ABC17AE593

Q34286311-02087011-B301-4D0F-B7DA-B63483C5DD0E

Q34286311-04A11157-238F-4B1E-B673-5D470FD6CB48

Q34286311-078623D3-2948-46CA-9649-1207B0BF03A0

Q34286311-09805649-DBE0-454C-8D89-B6505CF0C406

Q34286311-0E08DB2F-29D1-4F68-940F-AEF1BD2395F8

Q34286311-27E20097-0941-4464-96C5-81B2023CCAED

Q34286311-2C350FFF-CDCB-4AC1-8D97-1F7057CAC043

Q34286311-315E63BA-57F9-4477-950E-A67764558A62

Q34286311-329056E6-B6C1-4154-A919-40FF42F47838

P304

Q34286311-6948A04F-6BB3-4896-8650-4ECA254AF31C

P31

Q34286311-2F0B3667-9268-4C73-8A54-4F8D6D02B11C

P356

Q34286311-0FF14A57-DCD9-4A14-903C-3AE1E53B0CF8

P407

Q34286311-1AADE102-87F7-4134-8E44-73CA036311DA

P478

Q34286311-D18173C0-4460-4593-8D09-DB7409F86DF7

P50

Q34286311-A0AC4931-0F02-44E3-A349-84604371C2EE

Q34286311-A2C00655-E4AE-41BC-8A2D-BE2384BB5BB2

P577

Q34286311-CFE9D892-9FAD-4769-9707-24585F8CE01B

P698

Q34286311-E8C57BAC-9284-4239-90EC-15184A89E265

P932

Q34286311-F500CCBA-F57C-468D-BCAE-6D0151F679FF

P356

P1433

P1476

Population based screening for chronic kidney disease: cost effectiveness study.

@en

P2093

Braden Manns

http://www.w3.org/2001/XMLSchema#string

Brenda Hemmelgarn

http://www.w3.org/2001/XMLSchema#string

Flora Au

http://www.w3.org/2001/XMLSchema#string

James Dong

http://www.w3.org/2001/XMLSchema#string

Scott Klarenbach

http://www.w3.org/2001/XMLSchema#string

T Carter Chiasson

http://www.w3.org/2001/XMLSchema#string

P2860

Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure

Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators

Cardiac risk factors and the use of cardioprotective medications in patients with chronic renal insufficiency

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification

A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients

Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data.

Diabetes in Ontario: determination of prevalence and incidence using a validated administrative data algorithm.

P304

c5869

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/BMJ.C5869

http://www.w3.org/2001/XMLSchema#string

P407

P478

341

http://www.w3.org/2001/XMLSchema#string

P50

Marcello Tonelli

Alberta Kidney Disease Network

P577

2010-11-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21059726

http://www.w3.org/2001/XMLSchema#string

P932

2975430

http://www.w3.org/2001/XMLSchema#string